Related Experiment Video
Updated: Aug 31, 2026
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Mixed-phenotype acute leukemia (MPAL) exhibits frequent mutations in DNMT3A and activated signaling genes
Olive S Eckstein1, Linghua Wang2, Jyotinder N Punia3
1Cancer and Hematology Centers, Texas Children's Hospital/Baylor College of Medicine, Houston, TX.
Abstract:
Mixed-phenotype acute leukemia (MPAL) is a heterogeneous group of poor-prognosis leukemias with immunophenotypic features of at least two cell lineages. The full spectrum of genetic mutations in this rare disease has not been elucidated, limiting our understanding of disease pathogenesis and our ability to devise targeted therapeutic strategies. Here, we sought to define the mutational landscape of MPAL by performing whole-exome sequencing on samples from 23 adult and pediatric MPAL patients. We identified frequent mutations of epigenetic modifiers, most notably mutations of DNMT3A, in 33% of adult MPAL patients. Mutations of activated signaling pathways, tumor suppressors, and transcription factors were also frequent. Importantly, many of the identified mutations are potentially therapeutically targetable, with agents currently available or in various stages of clinical development. Therefore, the mutational spectrum that we have identified provides potential biological insights and is likely to have clinical relevance for patients with this poor-prognosis disease.
Insights
This study reveals frequent genetic mutations in mixed-phenotype acute leukemia (MPAL), including epigenetic modifiers like DNMT3A. These findings offer insights into MPAL pathogenesis and identify potential therapeutic targets for this poor-prognosis leukemia.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Mixed-phenotype acute leukemia (MPAL) is a rare, aggressive leukemia characterized by features of multiple cell lineages.
- The genetic underpinnings of MPAL remain incompletely understood, hindering the development of targeted therapies.
Purpose of the Study:
- To comprehensively define the mutational landscape of MPAL.
- To identify potential therapeutic targets for MPAL based on its genetic profile.
Main Methods:
- Whole-exome sequencing was performed on samples from 23 adult and pediatric MPAL patients.
- Analysis focused on identifying recurrent genetic mutations across different functional categories.
Main Results:
- Frequent mutations were observed in epigenetic modifiers, with DNMT3A mutations found in 33% of adult MPAL patients.
- Mutations in activated signaling pathways, tumor suppressors, and transcription factors were also common.
- A significant proportion of identified mutations are potentially targetable with existing or investigational therapies.
Conclusions:
- The study elucidates the mutational spectrum of MPAL, providing crucial insights into its pathogenesis.
- The identified genetic alterations have significant clinical relevance and suggest potential avenues for targeted treatment strategies in MPAL.
